Krystal Biotech
Open
$261.39
Prev. Close
$261.39
High
$261.39
Low
$261.30
Market Snapshot
$7.54B
36.8
3.11
$290.51M
295
Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 295 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
emptyResult
Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 295 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Recently from Cashu
Insider Trading at Krystal Biotech Sparks Concerns Over Strategic Financial Decisions
Krystal Biotech's Insider Trading Raises Questions on Strategic Decisions In a noteworthy development for Krystal Biotech, a prominent player in the biotechnology sector, board member Rossi has execut…
Krystal Biotech Insider Trading Highlights Strategic Confidence Amidst Market Volatility
### Insights into Insider Activity at Krystal Biotech Krystal Biotech, a key player in the biotechnology sector, experiences notable insider trading activity that attracts attention from both investor…
Implications of Insider Transactions on Krystal Biotech's Corporate Governance and Future Outlook
Strategic Insider Transactions: A Glimpse into Krystal Biotech’s Corporate Dynamics In a noteworthy shift within Krystal Biotech, a prominent insider transaction has recently come to light. Board memb…
Analysts Signal Clinical and Regulatory Uncertainty at Krystal Biotech
Analyst signal flags clinical and regulatory uncertainty at Krystal Biotech Nine analysts issue ratings on Krystal Biotech over the past three months, producing a mixed set of views that underscore un…